Eupraxia Pharmaceuticals

(NASDAQ) EPRX

Current Price$7.06

Market Cap$436.67M

Since IPO (2021)+155%

5 YearN/A

1 Year+86%

1 Month+1%

Eupraxia Pharmaceuticals Financials at a Glance

Market Cap

$436.67M

Revenue (TTM)

$0.00

Net Income (TTM)

$47.46M

EPS (TTM)

$-1.02

P/E Ratio

-6.97

Dividend

$0.00

Beta (Volatility)

0.00 (Low)

Dividend

$0.00

Beta (Volatility)

0.00 (Low)

Price

$7.06

Volume

904,099.223

Open

$7.07

Price

$7.06

Volume

904,099.223

Open

$7.07

Previous Close

$7.10

Daily Range

$6.85 - $7.36

52-Week Range

$3.82 - $9.32

Dividend

$0.00

Beta (Volatility)

0.00 (Low)

Price

$7.06

Volume

904,099.223

Open

$7.07

Previous Close

$7.10

Daily Range

$6.85 - $7.36

52-Week Range

$3.82 - $9.32

EPRX News

No articles available.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Eupraxia Pharmaceuticals

Industry

Biotechnology

Sector

Health Care

Employees

CEO

James A. Helliwell, MD

Website

www.eupraxiapharma.com

Headquarters

Victoria, BC V8R 5G4, CA

EPRX Financials

Key Financial Metrics (TTM)

Gross Margin

Operating Margin

Net Income Margin

Return on Equity

-53%

Return on Capital

-36%

Return on Assets

-32%

Earnings Yield

-14.35%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$436.67M

Shares Outstanding

61.50M

Volume

904.10K

Avg. Volume

213.74K

Financials (TTM)

Gross Profit

$331.89K

Operating Income

$53.66M

EBITDA

$53.33M

Operating Cash Flow

$29.03M

Capital Expenditure

$598.77K

Free Cash Flow

$29.63M

Cash & ST Invst.

$80.56M

Total Debt

$154.36K

Eupraxia Pharmaceuticals Performance Analysis

Revenue Growth Rate

Annual and quarterly growth comparison

Currently no data to display.

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name

Q1 2026YOY CHG

Revenue

$0.00

N/A

Gross Profit

$88.90K

N/A

Gross Margin

0.00%

N/A

Market Cap

$436.67M

N/A

Market Cap/Employee

$13.23M

N/A

Employees

N/A

Net Income

$12.48M

-29.6%

EBITDA

$15.65M

-63.6%

Quarterly Fundamentals

Name

Q1 2026YOY CHG

Net Cash

$137.32M

+401.1%

Accounts Receivable

$665.42K

+179.0%

Inventory

$0.00

N/A

Long Term Debt

$1.81M

N/A

Short Term Debt

$407.69K

+672.5%

Return on Assets

-32.25%

N/A

Return on Invested Capital

-36.10%

N/A

Free Cash Flow

$10.33M

-67.3%

Operating Cash Flow

$10.01M

-66.7%

Other Investments to Explore

People Also Watch

SymbolSymbol / CompanyCompanyPricePrice Chg

GNFTGenfit S.A.

GNFTGenfit S.A.$8.95+4.07%

NAUTNautilus Biotechnology, Inc.

NAUTNautilus Biotechnology, Inc.$2.54+0.00%

IVAInventiva S.A.

IVAInventiva S.A.$5.07-2.69%

OBIOOrchestra BioMed Holdings, Inc.

OBIOOrchestra BioMed Holdings, Inc.$4.06-0.98%

RNACCartesian Therapeutics, Inc.

RNACCartesian Therapeutics, Inc.$6.75+1.05%

TARAProtara Therapeutics, Inc.

TARAProtara Therapeutics, Inc.$4.92-1.01%

MDWDMediWound Ltd.

MDWDMediWound Ltd.$16.58-1.54%

Trending Stocks

SymbolSymbol / CompanyCompanyPricePrice Chg

AALAmerican Airlines Group

AALAmerican Airlines Group$13.85+0.02%

TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x Shares

TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x Shares$15.26+0.04%

INFQInfleqtion

INFQInfleqtion $16.35+0.11%

TET1 Energy Inc.

TET1 Energy Inc.$8.08-0.07%

FUTUFutu

FUTUFutu$89.76-0.28%

SQQQProShares Trust - ProShares UltraPro Short Qqq

SQQQProShares Trust - ProShares UltraPro Short Qqq$41.50-0.01%

HPQHP

HPQHP$25.24+0.15%

Questions About EPRX

What is the current price of Eupraxia Pharmaceuticals?

Eupraxia Pharmaceuticals is trading at $7.10 per share.

What is the 52-week range for Eupraxia Pharmaceuticals?

Over the past 52 weeks, Eupraxia Pharmaceuticals has traded between $3.82 and $9.32.

How much debt does Eupraxia Pharmaceuticals have?

As of the most recent reporting period, Eupraxia Pharmaceuticals reported total debt of $2.01M.

How much cash does Eupraxia Pharmaceuticals have on hand?

Eupraxia Pharmaceuticals reported $58.50M in cash and cash equivalents in its most recent financial results.

What is Eupraxia Pharmaceuticals’s dividend yield?

Eupraxia Pharmaceuticals does not currently have a dividend yield.

Eupraxia Pharmaceuticals

Eupraxia Pharmaceuticals Financials at a Glance

EPRX News

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

About Eupraxia Pharmaceuticals

EPRX Financials

Key Financial Metrics (TTM)

Stock Overview

Financials (TTM)

Eupraxia Pharmaceuticals Performance Analysis

Revenue Growth Rate

Earnings Per Share Growth Rate

Quarterly Performance

Quarterly Fundamentals

Other Investments to Explore

People Also Watch

Trending Stocks

Questions About EPRX

What is the current price of Eupraxia Pharmaceuticals?

What is the 52-week range for Eupraxia Pharmaceuticals?

How much debt does Eupraxia Pharmaceuticals have?

How much cash does Eupraxia Pharmaceuticals have on hand?

What is Eupraxia Pharmaceuticals’s dividend yield?

Premium Investing Services